By Maxx Chatsko Development delays across the pipeline risks losing interest on Wall Street, which has the attention span of a goldfish. Slow and steady may win the race, but the approach can still be frustrating. That’s especially true when Wall Street is involved. Krystal Biotech (KRYS) – Get Krystal Biotech Inc. Report provided a third-quarter 2022 business update on Nov. 7 that presented little new information. The company summarized recent announcements and kicked development timelines further into the future. Investors now have to wait even longer for the company to initiate the next pha…